Skip to content
DataLookout
Menu

NCT05733143

Using Exercise-testing to Explore Patient Differences in Severe Asthma

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words Show 7 more changesShow less
    • Trial completed
    • Final enrollment: 72 participants (planned 64)
    • Primary completion date changed from estimate of Nov 1, 2025 to Jun 24, 2024
    • Study completion date changed from estimate of Nov 30, 2025 to Jan 28, 2025
    • Study description expanded, about 24 words
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Notable Primary completion date: May 1, 2024 to Nov 1, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Sep 30, 2024 to Nov 30, 2025
    • Site details revised
    v4
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study completion date: Jun 1, 2024 to Sep 30, 2024
    • Start date changed from estimate of May 21, 2023 to Jul 18, 2023
    • Site details revised
    v3
  4. Notable Start date: Mar 1, 2023 to May 21, 2023
    • Primary completion date: Mar 1, 2024 to May 1, 2024
    • Study completion date: Apr 2024 to Jun 1, 2024
    v2
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

OBJECTIVES AND OUTCOME MEASURES
Timeframe: 6 months

Arms and interventions

Symptom high/T2-biomarker low (20 participants)

\[ACQ≥ 1.5 FeNO\<20 ppb AND blood eosinophil count\<150 cells/µL\]. During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.

Symptom low/T2-biomarker high (20 participants)

\[ACQ\<1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.

Symptom low/T2-biomarker low (12 participants)

\[ACQ\<1.5 AND FeNO\<20 ppb AND blood eosinophil count\<150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.

Symptom high/T2-biomarker high (12 participants)

\[ACQ≥ 1.5 AND FeNO≥20 ppb AND blood eosinophil count≥150 cells/µL\] During the study visit patients will undergo the following; COVID Lateral flow test (24 and 48 hours prior to assessment visit), Informed consent, Medical history and baseline demographics, vital Signs measurements, Weight/Height/BMI, Medication review, Concomitant medication check including technique, medical adherence, and self-management plan, Physical examination, Urine pregnancy test (If relevant), HADS score for depression, HADS score for anxiety, ACQ-5, Mini-AQLQ (QoL), St Georges Respiratory Questionnaire (SGRQ), Nijmegen hyperventilation score, BORG score, WHO Physical Global Activity Questionnaire (GPAQ), Haematology (FBC), Bio-banked samples: EDTA and urine(Eicosanoids), Spirometry, FeNO, Exercise test (CPEST) At 6 month follow up, in routine clinical care, participants will complete the same assessments. They will not be required to provide samples for biobanking or perform a repeat CPEST.

Other: cardiopulmonary exercise stress test (CPEST)

Sites

1 site in 1 country

  • Queen's University BelfastBelfast, Northern Ireland, United Kingdom